Clinical trial
Personalized NK Cell Therapy in CBT
NCT02727803 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Personalized NK Cell Therapy in CBT
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 19, 2016
- Completion date
- May 31, 2027
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, acute biphenotypic leukemia, acute lymphoblastic leukemia, acute lymphoblastic leukemia in remission, acute myeloid leukemia with myelodysplasia-related changes, acute myeloid leukemia with variant mll translocations, b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, chemotherapy-related leukemia, chronic myelomonocytic leukemia, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, iss stage ii plasma cell myeloma, iss stage iii plasma cell myeloma, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with gene mutation, myelodysplastic/myeloproliferative neoplasm, previously treated myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent adult acute myeloid leukemia, recurrent hodgkin lymphoma, recurrent non-hodgkin lymphoma, refractory acute lymphoblastic leukemia, refractory adult acute lymphoblastic leukemia, secondary acute myeloid leukemia, therapy-related myelodysplastic syndrome